Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
Two first analyses of our clinical trial on TIL as adjuvant therapy for melanoma were published in 2002 and 2007. We present here an update of the clinical results after a 17-year median followup. In this trial, disease-free patients were randomly assigned to receive either TIL/IL-2 or IL-2. The rel...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987883/ https://www.ncbi.nlm.nih.gov/pubmed/24741578 http://dx.doi.org/10.1155/2014/186212 |
_version_ | 1782311946678173696 |
---|---|
author | Khammari, Amir Knol, Anne-Chantal Nguyen, Jean-Michel Bossard, Céline Denis, Marc-Guillaume Pandolfino, Marie-Christine Quéreux, Gaëlle Bercegeay, Sylvain Dréno, Brigitte |
author_facet | Khammari, Amir Knol, Anne-Chantal Nguyen, Jean-Michel Bossard, Céline Denis, Marc-Guillaume Pandolfino, Marie-Christine Quéreux, Gaëlle Bercegeay, Sylvain Dréno, Brigitte |
author_sort | Khammari, Amir |
collection | PubMed |
description | Two first analyses of our clinical trial on TIL as adjuvant therapy for melanoma were published in 2002 and 2007. We present here an update of the clinical results after a 17-year median followup. In this trial, disease-free patients were randomly assigned to receive either TIL/IL-2 or IL-2. The relapse-free survival (RFS) was the primary objective. Eighty-eight patients were enrolled. A new analysis performed in May 2013 did not show significant changes in RFS or OS duration. However, our first finding on the association between the number of invaded lymph nodes and TIL effectiveness was strengthened. The Cox model adjusted on this interaction showed for the first time a significant treatment effect when considering the overall population, both on the RFS and OS. Patients treated with TIL had a longer RFS (P = 0.023) or OS (P = 0.020). This study being with a very long followup (17 years), confirmed the association between TIL effectiveness and the number of invaded lymph nodes, indicating that a low tumor burden could be a crucial factor enhancing the curative effect of TIL in possible microscopic residual disease. Moreover, we confirmed that a prolonged survival was associated with the presence of specific TIL and a decrease in Foxp3 expression. |
format | Online Article Text |
id | pubmed-3987883 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-39878832014-04-16 Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival Khammari, Amir Knol, Anne-Chantal Nguyen, Jean-Michel Bossard, Céline Denis, Marc-Guillaume Pandolfino, Marie-Christine Quéreux, Gaëlle Bercegeay, Sylvain Dréno, Brigitte J Immunol Res Clinical Study Two first analyses of our clinical trial on TIL as adjuvant therapy for melanoma were published in 2002 and 2007. We present here an update of the clinical results after a 17-year median followup. In this trial, disease-free patients were randomly assigned to receive either TIL/IL-2 or IL-2. The relapse-free survival (RFS) was the primary objective. Eighty-eight patients were enrolled. A new analysis performed in May 2013 did not show significant changes in RFS or OS duration. However, our first finding on the association between the number of invaded lymph nodes and TIL effectiveness was strengthened. The Cox model adjusted on this interaction showed for the first time a significant treatment effect when considering the overall population, both on the RFS and OS. Patients treated with TIL had a longer RFS (P = 0.023) or OS (P = 0.020). This study being with a very long followup (17 years), confirmed the association between TIL effectiveness and the number of invaded lymph nodes, indicating that a low tumor burden could be a crucial factor enhancing the curative effect of TIL in possible microscopic residual disease. Moreover, we confirmed that a prolonged survival was associated with the presence of specific TIL and a decrease in Foxp3 expression. Hindawi Publishing Corporation 2014 2014-01-08 /pmc/articles/PMC3987883/ /pubmed/24741578 http://dx.doi.org/10.1155/2014/186212 Text en Copyright © 2014 Amir Khammari et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Khammari, Amir Knol, Anne-Chantal Nguyen, Jean-Michel Bossard, Céline Denis, Marc-Guillaume Pandolfino, Marie-Christine Quéreux, Gaëlle Bercegeay, Sylvain Dréno, Brigitte Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival |
title | Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival |
title_full | Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival |
title_fullStr | Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival |
title_full_unstemmed | Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival |
title_short | Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival |
title_sort | adoptive til transfer in the adjuvant setting for melanoma: long-term patient survival |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987883/ https://www.ncbi.nlm.nih.gov/pubmed/24741578 http://dx.doi.org/10.1155/2014/186212 |
work_keys_str_mv | AT khammariamir adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT knolannechantal adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT nguyenjeanmichel adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT bossardceline adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT denismarcguillaume adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT pandolfinomariechristine adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT quereuxgaelle adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT bercegeaysylvain adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT drenobrigitte adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival |